SMS Pharmaceuticals Q1 FY27: Revenue ₹207 Cr, PAT ₹20 Cr
Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹207Cr
- +5.6% YoY
- −13% QoQ
- Net profit
- ₹21Cr
- +5% YoY
- −36.4% QoQ
- Margin
- 20%
- 0 pp YoY
- +3 pp QoQ
Guidance rank: #51 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on SMS Pharmaceuticals Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q1FY27 revenue from operations: ₹207 crore, up 6% YoY (Page 6, 5) - Q1FY27 EBITDA: ₹41 crore, up 4% YoY (Page 6) - Q1FY27 PAT: ₹20 crore, up 8% YoY (Page 6) - EPS for Q1FY27: ₹2.23 (Page 6) - Revenue from operations for FY26: ₹586.87 crore, up 13% YoY from FY25 (₹782.75 crore appears to be a typo or formatting issue; likely FY25 revenue was ₹782.75 crore as a base) (Page 27) - Gross margin steady at around 34-36% in Q1FY27 (Page 27) - Quarterly (Q1FY27) figures: - EBITDA: ₹41 crore, up 4% YoY - EBITDA Margin: 20%, sustained QoQ and YoY - PAT: ₹20 crore, up 8% YoY - PAT Margin: 10%, up slightly YoY - Year-on-Year (YoY)
From SMS Pharmaceuticals Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Q1FY27 revenue from operations: ₹207 crore, up 6% YoY (Page 6, 5)
- Q1FY27 EBITDA: ₹41 crore, up 4% YoY (Page 6)
- Q1FY27 PAT: ₹20 crore, up 8% YoY (Page 6)
- EPS for Q1FY27: ₹2.23 (Page 6)
- Revenue from operations for FY26: ₹586.87 crore, up 13% YoY from FY25 (₹782.75 crore appears to be a typo or formatting issue; likely FY25 revenue was ₹782.75 crore as a base) (Page 27)
- Gross margin steady at around 34-36% in Q1FY27 (Page 27)
2 more points from SMS Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what SMS Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
2 more points from SMS Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what SMS Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what SMS Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.
SMS Pharmaceuticals Ltd — Quarterly revenue & net profit
SMS Pharmaceuticals Ltd Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 207 | 196 | +5.6% | 238 | -13% |
| Operating profit (EBITDA) | 41 | 39 | +5.1% | 40 | +2.5% |
| Operating margin | 20% | 20% | 0 pp | 17% | +3 pp |
| Profit before tax | 27 | 24 | +12.5% | 27 | 0% |
| Net profit (PAT) | 21 | 20 | +5% | 33 | -36.4% |
| EPS (₹) | 2.23 | 2.31 | -3.5% | 3.49 | -36.1% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹316 Cr, net profit ₹40 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What SMS Pharmaceuticals's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
SMS Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were SMS Pharmaceuticals Ltd Q1 FY27 results?
Q1FY27 revenue from operations: ₹207 crore, up 6% YoY (Page 6, 5) - Q1FY27 EBITDA: ₹41 crore, up 4% YoY (Page 6) - Q1FY27 PAT: ₹20 crore, up 8% YoY (Page 6) - EPS for Q1FY27: ₹2.23 (Page 6) - Revenue from operations for FY26: ₹586.87 crore, up 13% YoY from FY25 (₹782.75 crore appears to be a typo or formatting issue; likely FY25 revenue was ₹782.75 crore as a base) (Page 27) - Gross margin steady at around 34-36% in Q1FY27 (Page 27) - Quarterly (Q1FY27) figures: - EBITDA: ₹41 crore, up 4% YoY - EBITDA Margin: 20%, sustained QoQ and YoY - PAT: ₹20 crore, up 8% YoY - PAT Margin: 10%, up slightly YoY - Year-on-Year (YoY)
What is SMS Pharmaceuticals Ltd share price analysis?
SMS Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 40.5 with a market cap of ₹4,148 Cr. Investors should review the full earnings analysis for detailed insights.
Is SMS Pharmaceuticals Ltd planning capital expenditure?
Capex spend of ₹280 crore planned to be completed by FY27 (Page 25).
Keep SMS Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
